| Style | Citing Format |
|---|---|
| MLA | Jahan Mehmani E, et al.. "A Cost-Efficient Internal Standard Approach for Busulfan Quantification: Ms-Based Investigation of Adduct Formation in Therapeutic Drug Monitoring." DARU, Journal of Pharmaceutical Sciences, vol. 34, no. 2, 2026, pp. -. |
| APA | Jahan Mehmani E, Rastegarpanah N, Zarei I, Amanlou M (2026). A Cost-Efficient Internal Standard Approach for Busulfan Quantification: Ms-Based Investigation of Adduct Formation in Therapeutic Drug Monitoring. DARU, Journal of Pharmaceutical Sciences, 34(2), -. |
| Chicago | Jahan Mehmani E, Rastegarpanah N, Zarei I, Amanlou M. "A Cost-Efficient Internal Standard Approach for Busulfan Quantification: Ms-Based Investigation of Adduct Formation in Therapeutic Drug Monitoring." DARU, Journal of Pharmaceutical Sciences 34, no. 2 (2026): -. |
| Harvard | Jahan Mehmani E et al. (2026) 'A Cost-Efficient Internal Standard Approach for Busulfan Quantification: Ms-Based Investigation of Adduct Formation in Therapeutic Drug Monitoring', DARU, Journal of Pharmaceutical Sciences, 34(2), pp. -. |
| Vancouver | Jahan Mehmani E, Rastegarpanah N, Zarei I, Amanlou M. A Cost-Efficient Internal Standard Approach for Busulfan Quantification: Ms-Based Investigation of Adduct Formation in Therapeutic Drug Monitoring. DARU, Journal of Pharmaceutical Sciences. 2026;34(2):-. |
| BibTex | @article{ author = {Jahan Mehmani E and Rastegarpanah N and Zarei I and Amanlou M}, title = {A Cost-Efficient Internal Standard Approach for Busulfan Quantification: Ms-Based Investigation of Adduct Formation in Therapeutic Drug Monitoring}, journal = {DARU, Journal of Pharmaceutical Sciences}, volume = {34}, number = {2}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Jahan Mehmani E AU - Rastegarpanah N AU - Zarei I AU - Amanlou M TI - A Cost-Efficient Internal Standard Approach for Busulfan Quantification: Ms-Based Investigation of Adduct Formation in Therapeutic Drug Monitoring JO - DARU, Journal of Pharmaceutical Sciences VL - 34 IS - 2 SP - EP - PY - 2026 ER - |